Search details
1.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials.
Haematologica
; 109(1): 245-255, 2024 01 01.
Article
in English
| MEDLINE | ID: mdl-37439329
2.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.
Hematol Oncol
; 42(4): e3290, 2024 Jul.
Article
in English
| MEDLINE | ID: mdl-38818978
3.
Biological features and outcome of diffuse large B-cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective 'Elderly Project' by the Fondazione Italiana Linfomi.
Br J Haematol
; 201(4): 653-662, 2023 05.
Article
in English
| MEDLINE | ID: mdl-36733229
4.
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
Haematologica
; 108(8): 2091-2100, 2023 08 01.
Article
in English
| MEDLINE | ID: mdl-36632738
5.
The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection.
Haematologica
; 100(2): 246-52, 2015 Feb.
Article
in English
| MEDLINE | ID: mdl-25381127
Results
1 -
5
de 5
1
Next >
>>